Branaplam was originally developed as a splice enhancer of exon 7 in the SMN2 gene, which increases full-length SMN2 protein and compensates for loss of SMN1 function in spinal muscular atrophy[44]. This evidence concerns the gene SMN2 and spinal muscular atrophy.